Loading

Investor Relations

Corporate Profile

We are a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with various conditions. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor, or NK1R, given as a once daily, oral tablet, has the potential to significantly alleviate pruritus associated with various conditions.

Copyright West LLC. Minimum 15 minutes delayed.

Events

Menlo Therapeutics to Participate in the 30th Annual Piper Jaffray Healthcare Conference

REDWOOD CITY, Calif. , Nov. 16, 2018 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus associated with various conditions, today announced that Steve Basta , Chief Executive

Menlo Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update

~ Phase 2 Data in Psoriasis Expected December 2018 ~ ~ New Phase 2 Clinical Trial in Chronic Pruritus of Unknown Origin Expected to Start in Q4 2018 ~ ~ Prurigo Nodularis Phase 3 Clinical Trials Enrolling in U.S. and Europe ~ REDWOOD CITY, Calif. , Nov.

Menlo Therapeutics Announces Results from a Phase 2 Clinical Trial of Serlopitant for the Treatment of Refractory Chronic Cough

Serlopitant fails to demonstrate efficacy relative to placebo on primary and secondary endpoints REDWOOD CITY, Calif. , Oct. 08, 2018 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO) a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of